论文部分内容阅读
目的:采用新辅助化疗方法进行宫颈癌患者的术前治疗。方法:应用吉西它滨+顺铂方案9例,其他含铂方案16例,不含铂方案2例,化疗间隔3～4周,化疗疗程数1～3个。结果:27例宫颈癌患者术前行新辅助化疗的总有效率为62.96%(17/27),完全缓解率为7.41%(2/27),部分缓解率为55.56%(15/27),病情稳定37.04%(10/27),无一例出现疾病进展。结论:宫颈癌术前新辅助化疗可以缩减肿瘤的体积和范围,降低肿瘤的分期,提高手术治疗效果。
Objective: To adopt neoadjuvant chemotherapy for preoperative treatment of cervical cancer patients. Methods: Nine cases were treated with gemcitabine plus cisplatin, 16 cases with other platinum-containing regimens, 2 cases without platinum regimen, 3 to 4 weeks after chemotherapy, and 1 to 3 chemotherapy regimens. Results: The total effective rate of neoadjuvant chemotherapy in 27 cases of cervical cancer was 62.96% (17/27), the complete remission rate was 7.41% (2/27), the partial remission rate was 55.56% (15/27) Stable condition 37.04% (10/27), no case of disease progression. Conclusion: Neoadjuvant chemotherapy before cervical cancer can reduce the size and scope of the tumor, reduce the tumor staging, and improve the effect of surgical treatment.